Circadian variation in methotrexate toxicity in streptozotocin-induced diabetes mellitus rats

Abstract The effects of diabetes mellitus and circadian rhythm on pharmacokinetics or pharmacodynamics of drugs have been previously separately reviewed. In our previous study, a circadian rhythm has been described in the pharmacokinetics of MTX in streptozotocin-induced diabetes mellitus (SIDM) rats. The aim of the present study was to investigate the effects of circadian rhythm on the toxicity of MTX in SIDM rats. The hematologic parameters and serum folic acid levels were measured in control and SIDM groups before and after MTX administration to evaluate its toxicity. We observed that circadian rhythm in basal peripheral WBC counts disappeared after MTX administration in the first hour and were phase shifted on the fifth day. Circadian variations were not observed in the other blood cells. One hour after MTX administration, folic acid levels were high in both groups. However, a circadian rhythm was present only in the diabetic group. The alteration in the rhythm of WBC counts in diabetic rats may originate not only from the effect of MTX but also physiological alterations due to diabetes and/or the varying cell cycle entry rates in the hematopoetic stem cells.

[1]  M. Gumustekin,et al.  The role of circadian rhythm on the pharmacokinetic of methotrexate in streptozotocin-induced diabetes mellitus rats , 2005 .

[2]  J. Radziuk,et al.  Endogenous Glucose Production in Type 2 Diabetes: Basal and Postprandial. Role of Diurnal Rhythms , 2004, Journal of Investigative Medicine.

[3]  A. Ramanan,et al.  Use of methotrexate in juvenile idiopathic arthritis , 2003, Archives of disease in childhood.

[4]  A. Prémaud,et al.  An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine. , 2002, Toxicology and applied pharmacology.

[5]  J. Radziuk,et al.  Quantitation of basal endogenous glucose production in Type II diabetes: importance of the volume of distribution , 2002, Diabetologia.

[6]  P. Quesenberry,et al.  Physical and physiological plasticity of hematopoietic stem cells. , 2001, Blood cells, molecules & diseases.

[7]  W. Hrushesky,et al.  Circadian organization of thymidylate synthase activity in normal tissues: A possible basis for 5‐fluorouracil chronotherapeutic advantage , 2000, International journal of cancer.

[8]  I. Goldman,et al.  The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  I. Goldman,et al.  Discrimination among reduced folates and methotrexate as transport substrates by a phenylalanine substitution for serine within the predicted eighth transmembrane domain of the reduced folate carrier. , 1999, Biochemical pharmacology.

[10]  M. Rots,et al.  Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. , 1999, Blood.

[11]  Y. Jung,et al.  Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. , 1998, Research Communications in Molecular Pathology and Pharmacology.

[12]  So H. Kim,et al.  Pharmacokinetics of a new carbapenem, DA‐1131, after intravenous administration to rats with alloxan‐induced diabetes mellitus , 1998, Biopharmaceutics & drug disposition.

[13]  Y. Assaraf,et al.  A Reduced Folate Carrier Mutation Produces Substrate-dependent Alterations in Carrier Mobility in Murine Leukemia Cells and Methotrexate Resistance with Conservation of Growth in 5-Formyltetrahydrofolate* , 1998, The Journal of Biological Chemistry.

[14]  I. Ashkenazi,et al.  Alterations of Circadian Rhythms in Mice Induced by Anti-Cancer Drugs , 1998 .

[15]  J. M. Park,et al.  Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats. , 1996, Research communications in molecular pathology and pharmacology.

[16]  M. Aldegunde,et al.  Platelet serotonin transport is altered in streptozotocin-induced diabetic rats. , 1995, Life sciences.

[17]  W. Hrushesky,et al.  Circadian cancer therapy. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Gwilt,et al.  The Effects of Diabetes Mellitus on Pharmacokinetics and Pharmacodynamics in Humans , 1991, Clinical pharmacokinetics.

[19]  G. Koren,et al.  Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. , 1990, American journal of diseases of children.

[20]  T. Hasegawa,et al.  Effect of diabetes on disposition and renal handling of cefazolin in rats. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[21]  J. Feely,et al.  Clinical Pharmacokinetics and Endocrine Disorders , 1987, Clinical pharmacokinetics.

[22]  M. Terrissol,et al.  Chronotoxicity of methotrexate in mice after intraperitoneal administration. , 1987, Chronobiologia.

[23]  P. Winocour,et al.  Platelet survival in rats with spontaneous diabetes mellitus. , 1987, The Journal of laboratory and clinical medicine.

[24]  M. Laimins,et al.  Platelet Survival in Streptozotocin-Induced Diabetic Rats , 1984, Thrombosis and Haemostasis.

[25]  F. Lévi,et al.  Lethal nephrotoxicity and hematologic toxicity of cis-diamminedichloroplatinum ameliorated by optimal circadian timing and hydration. , 1982, European journal of cancer & clinical oncology.

[26]  J. Arendt,et al.  The effect of abolition of the endogenous corticosteroid rhythm on the circadian variation in methotrexate toxicity in the rat , 2004, Cancer Chemotherapy and Pharmacology.

[27]  G. Ferrazzini,et al.  Diurnal variation of methotrexate disposition in children with acute leukaemia , 2004, European Journal of Clinical Pharmacology.

[28]  Y. Assaraf,et al.  Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells. , 1997, Advances in enzyme regulation.

[29]  G. Bjarnason.  Clinical chronotolerance to anticancer drugs: relevance for dose-intensity. , 1995, In Vivo.

[30]  E. Mammen,et al.  The effect of streptozocin-induced diabetes on platelet aggregation as determined by impedance aggregometry and platelet secretion: a possible role for nitric oxide. , 1995, Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians.

[31]  T. Cachero,et al.  Circadian rhythms of plasma corticosterone at different times after induction of diabetes. Responses to corticoadrenal stimulation in light and dark phases. , 1993, Life sciences.

[32]  G. Koren,et al.  Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. , 1992, Chronobiology international.

[33]  B. Lange,et al.  Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? , 1989, The American journal of pediatric hematology/oncology.

[34]  F. Balis,et al.  Central nervous system pharmacology of antileukemic drugs. , 1989, The American journal of pediatric hematology/oncology.

[35]  U. Eriksson,et al.  Increased platelet volume in manifest diabetic rats. , 1983, Upsala journal of medical sciences.

[36]  J. Neff,et al.  Hematological Characteristics of the BB Wistar Rat. , 1983, Veterinary clinical pathology.